Andrew Briggs, DPhil

William R Lindsay Chair in Health Economics
University of Glasgow
Health Economics & Health Technology Assessment
University of Glasgow
1 Lilybank Gardens
Glasgow United Kingdom G12 8RZ


Biographical Sketch: Andrew holds the William R Lindsay Chair in Health Economics at the University of Glasgow. Previously, he held the position of Reader in Health Economics at the University of Oxford's Health Economics Research Centre (HERC). In addition, he spent the academic year 1999/2000 at the Centre for Evaluation of Medicines (CEM), at McMaster University and he remains a research associate of both CEM and HERC. Andrew has expertise in all areas of health economic evaluation -- he has published well over 100 articles in the peer-reviewed literature. He has particularly focused on statistical methods for cost-effectiveness analysis. This includes statistical methods for estimation of parameters for cost-effectiveness models as well as statistical analysis of cost-effectiveness alongside clinical trials. He also has a more general interest in epidemiological methods, in particular the use of prognostic scoring methods for predicting health outcomes and the relationship with heterogeneity in cost-effectiveness. Andrew recently took a leadership role as co-chair of the Joint Society for Medical Decision Making (SMDM) and International Society for PharamacoEconomics and Outcomes Research (ISPOR) Task Force on Modelling Methods. The Task Force, which was responsible for producing a set of seven papers covering all aspects of modelling methods applied to medical decision making and health technology assessment. He is also the author of two successful textbooks, one published by OUP entitled Decision Modelling for Health Economic Evaluation, and another published by Wiley entitled Statistical Methods for Cost-Effectiveness Analysis. In addition to his role at the University of Glasgow, he also serves as Editor of the journal Health Economics, Associate Editor for the journal Medical Decision Making, and is on the editorial board of Value in Health.

Papers:
1C-3 PROBABILISTIC SENSITIVITY ANALYSIS IN MICROSIMULATION MODELS: FINDING THE RIGHT BALANCE PRIORITIZING INDIVIDUALS FOR PREVENTIVE STATIN THERAPY: BEYOND TEN-YEAR RISK SIGNALLING DEMAND: PCSK9 INHIBITORS FOR STATIN INTOLERANT INDIVIDUALS AM6 UNDERSTANDING SURVIVAL MODELLING WITH APPLICATION TO HTA